Review
Oncology
Ashley C. Woods, Kelly J. Norsworthy
Summary: Differentiation syndrome (DS) is a potentially life-threatening clinical syndrome associated with targeted therapeutics for acute promyelocytic leukemia (APL) and acute myeloid leukemia (AML). It is characterized by fever, dyspnea, hypotension, weight gain, effusions, and renal failure. Diagnosing and managing DS require individualized approaches.
Article
Oncology
Luciana Yamamoto de Almeida, Diego A. Pereira-Martins, Isabel Weinhaeuser, Cesar Ortiz, Larissa A. Candido, Ana Paula Lange, Nayara F. De Abreu, Silvia E. S. Mendonza, Virginia M. de Deus Wagatsuma, Mariane C. Do Nascimento, Helder H. Paiva, Raquel M. Alves-Paiva, Camila C. O. M. Bonaldo, Daniele C. Nascimento, Jose C. Alves-Filho, Priscila S. Scheucher, Ana Silvia G. Lima, Jan Jacob Schuringa, Emanuele Ammantuna, Tiziana Ottone, Nelida I. Noguera, Cleide L. Araujo, Eduardo M. Rego
Summary: This study revealed that the EGFR pathway is active in APL patients, and the use of EGFR inhibitors can promote differentiation of APL cells, providing a potential strategy to alleviate resistance to ATRA and ATO.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Harinder Gill, Radha Raghupathy, Carmen Y. Y. Lee, Yammy Yung, Hiu-Tung Chu, Michael Y. Ni, Xiao Xiao, Francis P. Flores, Rita Yim, Paul Lee, Lynn Chin, Vivian W. K. Li, Lester Au, Wing-Yan Au, Edmond S. K. Ma, Diwakar Mohan, Cyrus Rustam Kumana, Yok-Lam Kwong
Summary: This study found that the incidence of acute promyelocytic leukaemia (APL) is increasing, and the use of oral arsenic trioxide (oral-ATO) in treatment has significantly improved patient survival rates.
Review
Oncology
Andrei Colita, Alina Daniela Tanase, Ciprian Tomuleasa, Anca Colita
Summary: Acute promyelocytic leukemia (APL) patients who relapse, despite treatment with all-trans retinoic acid and arsenic trioxide, require a highly efficient consolidation treatment. Hematopoietic stem cell transplantation is recommended for these patients. However, there are still controversies regarding the role of transplantation in APL and further studies are needed.
Article
Oncology
Hong-Hu Zhu, Ya-Fang Ma, Kang Yu, Gui-Fang Ouyang, Wen-Da Luo, Ren-Zhi Pei, Wei-Qun Xu, Hui-Xian Hu, Shu-Ping Mo, Xiao-Hua Xu, Jian-Ping Lan, Jian-Ping Shen, Li-Hong Shou, Shen-Xian Qian, Wei-Ying Feng, Pu Zhao, Jin-Hong Jiang, Bei-Li Hu, Jin Zhang, Su-Ying Qian, Gong-Qiang Wu, Wen-Ping Wu, Lei Qiu, Lin-Jie Li, Xiang-Hua Lang, Sai Chen, Li-Li Chen, Jun-Bin Guo, Li-Hong Cao, Hui-Fang Jiang, Yong-Ming Xia, Jing Le, Jian-Zhi Zhao, Jian Huang, Yue-Feng Zhang, Ya-Li Lv, Jing-Sheng Hua, Yong-Wei Hong, Cui-Ping Zheng, Ju-Xiang Wang, Bin-Fei Hu, Xiao-Hui Chen, Li-Ming Zhang, Shi Tao, Bing-Shou Xie, Yue-Min Kuang, Wen-Ji Luo, Ping Su, Jun Guo, Xiao Wu, Wei Jiang, Hui-Qi Zhang, Yun Zhang, Chun-Mei Chen, Xiao-Feng Xu, Yan Guo, Jin-Ming Tu, Shao Hu, Xiao-Yan Yan, Chen Yao, Yin-Jun Lou, Jie Jin
Summary: This population-based study in Zhejiang Province, China, found that ATRA and arsenic as front-line treatment are widely used and have low early death rate and high survival rate in real-world conditions. These results mimic those from clinical trials, supporting the broader application of APL guidelines in the future.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Karoly Jambrovics, Szilard Poliska, Beata Scholtz, Ivan P. Uray, Zoltan Balajthy
Summary: Transglutaminase 2 (TG2) is a critical factor for cancer cell survival and is involved in various processes related to cancer progression. Arsenic trioxide (ATO) has shown potential in improving outcomes for acute promyelocytic leukaemia (APL) patients. In this study, it was demonstrated that ATO increased reactive oxygen species (ROS) production and apoptosis in leukaemia cells, and the deletion of TG2 enhanced these responses. Combined ATO and all-trans retinoic acid (ATRA) treatment also led to increased NRF2 expression and calpain proteolytic activity, resulting in TG2 degradation and reduced survival of leukaemia cells. Moreover, ATO treatment sensitized epithelial cells and peripheral blood mononuclear cells to apoptosis by degrading induced TG2 protein expression.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Yujiao Zhang, Quan Wu, Baoyi Yuan, Yun Huang, Ling Jiang, Fang Liu, Ping Yan, Yongshuai Jiang, Jieyu Ye, Xuejie Jiang
Summary: Platelet count at diagnosis has predictive value for therapeutic outcome in non-APL AML patients. Patients with specific genetic mutations may have different platelet counts at diagnosis.
Article
Materials Science, Ceramics
Wei Peng, Lingxia Li, Shihui Yu, Pan Yang, Kangli Xu
Summary: In this study, In-free SnO2:Sb/Au/SnO2:Sb (ATO/Au/ATO, SAS) tri-layer films were successfully prepared, showing high transparency and conductivity. These films are promising alternatives to ITO in flexible electronics applications due to their superior performance and properties.
CERAMICS INTERNATIONAL
(2022)
Editorial Material
Hematology
Rachel E. Rau
Summary: In this article, Astolfi et al. report the first cases of APL caused by the insertion of TTMV into the RARA locus, which expands our understanding of the pathogenesis of this disease.
Article
Oncology
Richard P. Tobin, Dasha T. Cogswell, Victoria M. Cates, Dana M. Davis, Jessica S. W. Borgers, Robert J. Van Gulick, Elizabeth Katsnelson, Kasey L. Couts, Kimberly R. Jordan, Dexiang Gao, Eduardo Davila, Theresa M. Medina, Karl D. Lewis, Rene Gonzalez, Ross W. McFarland, William A. Robinson, Martin D. McCarter
Summary: The purpose of this clinical trial was to evaluate the safety and efficacy of combining all-trans retinoic acid (ATRA) with pembrolizumab in patients with stage IV melanoma. The results showed that the combination was well tolerated and had a high response rate, making it a promising frontline treatment strategy for advanced melanoma.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Dorien Laenens, Yuling Yu, Beatrice Santens, Johanna Jacobs, Benoit Beuselinck, Oliver Bechter, Els Wauters, Jan Staessen, Stefan Janssens, Lucas Van Aelst
Summary: In rare cases, immune checkpoint inhibitors (ICIs) can lead to immune-mediated myocarditis. This study aimed to investigate the incidence rates and risk factors of major adverse cardiovascular events (MACEs) in cancer patients treated with ICIs, finding that patients with a history of cardiovascular disease are more at risk for MACE. Compared to cancer patients not treated with ICIs and the general population, those treated with ICIs had significantly higher incidence rates of MACE, suggesting a potential harmful effect of ICI treatment on cardiovascular events.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Editorial Material
Hematology
Eun-Ju Lee, James B. Bussel
Summary: In this article, the authors present encouraging results from a study on the use of ATRA in adult patients with ITP.
Editorial Material
Hematology
Qian-Fei Wang, Hong -Hu Zhu
Summary: In this study, Poplineau et al identified a retinoic acid resistance network involving the E2F-EZH2 axis in a PLZF-RARA transgenic acute promyelocytic leukemia mouse model. They demonstrated that the nonenzymatic activity of EZH2 is crucial for retinoic acid resistance. Targeting the pan-EZH2 activity significantly improved survival in mice reconstituted with retinoic acid-resistant PLZF-RARA leukemia cells.
Article
Virology
Xiaofei Niu, Hongyan Wang, Lihong Zhao, Pengjing Lian, Yu Bai, Jingyun Li, Jian Qiao
Summary: ATRA at therapeutic dose can increase the pathogenicity of H9N2 virus.
Article
Gastroenterology & Hepatology
Ferdinando Nicoletti, Laura Hammer, Stacia Furtado, Katia Mangano, Edith Mathiowitz, Benjamin Green, Dominick L. Auci
Summary: A poly(lactic-co-glycolic acid) (PLGA) microsphere encapsulated all-trans retinoic acid (ATRA) formulation was developed to target immune structures in the gut and limit systemic exposure, showing potential for attenuating inflammatory bowel disease (IBD).
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Hematology
Justin M. Watts, Maria R. Baer, Jay Yang, Thomas Prebet, Sangmin Lee, Gary J. Schiller, Shira N. Dinner, Arnaud Pigneux, Pau Montesinos, Eunice S. Wang, Karen P. Seiter, Andrew H. Wei, Stephane De Botton, Montserrat Arnan, Will Donnellan, Anthony P. Schwarer, Christian Recher, Brian A. Jonas, P. Brent Ferrell Jr, Christophe Marzac, Patrick Kelly, Jennifer Sweeney, Sanjeev Forsyth, Sylvie M. Guichard, Julie Brevard, Patrick Henrick, Hesham Mohamed, Jorge E. Cortes
Summary: This study evaluated the safety, pharmacokinetics, pharmacodynamics, and clinical activity of Olutasidenib in patients with acute myeloid leukemia or myelodysplastic syndrome with mutant IDH1. The results showed that Olutasidenib, as monotherapy or in combination with azacitidine, was well tolerated and exhibited meaningful clinical activity. These findings provide a rationale for further evaluation of Olutasidenib in different populations of patients with myeloid malignancies.
LANCET HAEMATOLOGY
(2023)
Article
Urology & Nephrology
Camilo Montero, Nancy Yomayusa, Rodolfo Torres, Jorge Cortes, Carlos Alvarez, Juan Gallo, Guillermo Aldana, Andres Acevedo, Maria Rios, Johana Echeverri, Zuly Yepes, Adriana Silva, Diana Gayon, Jorge Perez, Milciades Ibanez
Summary: This study aimed to evaluate asymptomatic CMV reactivation and CMV disease in kidney transplant recipients with positive CMV serostatus. The results showed that asymptomatic CMV reactivation was higher in patients who received thymoglobulin induction, while the rates of CMV disease were similar between the two treatment groups. The significant difference in asymptomatic CMV reactivation between the two groups did not affect graft function and histology.
Article
Oncology
Nikhil Shri Sahajpal, Ashis K. Mondal, Harmanpreet Singh, Ashutosh Vashisht, Sudha Ananth, Daniel Saul, Alex R. Hastie, Benjamin Hilton, Barbara R. DuPont, Natasha M. Savage, Vamsi Kota, Alka Chaubey, Jorge E. Cortes, Ravindra Kolhe
Summary: The current genetic testing of myeloid cancers lacks resolution and is limited to specific genomic regions/genes. This study used a combination of high-resolution cytogenetic technology and next-generation sequencing to obtain a comprehensive genomic profile of these tumors. The combinatorial approach identified new genetic alterations and clinically relevant alterations in previously negative cases.
Article
Hematology
Mycal Casey, Lorriane Odhiambo, Nidhi Aggarwal, Mahran Shoukier, K. M. Islam, Jorge Cortes
Summary: Despite advances in cancer outcomes, there are significant health disparities in the treatment of lymphomas. This study examined the representation of different demographic groups in randomized controlled trials (RCTs) for lymphoma and found significant underrepresentation of black, Hispanic, and female patients. Geographic distribution of trials also limited access for patients in certain areas. Correcting enrollment disparities is crucial to ensure that the results of these trials are applicable to all populations.
Article
Oncology
Fabio Efficace, Francesco Cottone, Betina Yanez, Vamsi Kota, Fausto Castagnetti, Giovanni Caocci, Massimiliano Bonifacio, Andrea Patriarca, Isabella Capodanno, Maria Cristina Miggiano, Mario Tiribelli, Massimo Breccia, Luigia Luciano, Valentina Giai, Alessandra Iurlo, Elisabetta Abruzzese, Carmen Fava, Shira Dinner, Jessica K. Altman, Gianantonio Rosti, Jorge Cortes, Marco Vignetti, David Cella
Summary: Patient-reported symptom monitoring from the beginning of therapy in patients with CML may be critical to improve adherence to therapy and early molecular response rates. The current findings suggest that systematic monitoring of patient-reported symptoms is associated with high adherence rates.
Article
Oncology
Koji Sasaki, Kiyomi Morita, Hagop Kantarjian, Guillermo Garcia-Manero, Elias Jabbour, Farhad Ravandi, Marina Konopleva, Gautam Borthakur, William Wierda, Naval Daver, Koichi Takahashi, Courtney Dinardo, Guillermo Montalban Bravo, Ghayas C. Issa, Sherry A. Pierce, Kelly A. Soltysiak, Martha S. Tingen, Jorge E. Cortes
Summary: This study investigated the impact of geographic disparities on cancer survival. The study found that factors such as age, income, race, and distance to cancer centers were predictive of survival. The results showed significant disparities in cancer care based on geographic locations.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Article
Virology
Pankaj Ahluwalia, Ashutosh Vashisht, Harmanpreet Singh, Nikhil Shri Sahajpal, Ashis K. Mondal, Kimya Jones, Jaspreet Farmaha, Ryan Bloomquist, Caroline Marie Carlock, Drew Fransoso, Christina Sun, Tyler Day, Comfort Prah, Trinh Vuong, Patty Ray, Danielle Bradshaw, Marisol Miranda Galvis, Sadanand Fulzele, Girindra Raval, Justin Xavier Moore, Jorge Cortes, Jeffrey N. James, Vamsi Kota, Ravindra Kolhe
Summary: This study aimed to investigate the temporal changes in the humoral immune response among healthcare workers in Augusta, GA, USA, and explore any associations with ethno-demographic features. The findings showed a significant decline in neutralizing antibody (NAb) and IgG levels at 8-12 months post-vaccination, with a more pronounced decline in White HCWs. Booster doses were found to increase antibody levels significantly, while participants without booster doses experienced a decline in antibody levels at 12 months post-vaccination.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Review
Hematology
Marisol Miranda-Galvis, Kellen C. Tjioe, E. Andrew Balas, Gagan Agrawal, Jorge E. Cortes
Summary: This article evaluates the impact of social determinants of health on the outcomes of patients with hematologic malignancies. The study found that factors such as education level, health insurance coverage, income level, and marital status significantly affect patients' survival rates. However, there are contradictory reports regarding the effect of distance to treatment centers on treatment outcomes. Additionally, data on transportation, debt, diet, and other factors are lacking.
Review
Hematology
Mahesh Swaminathan, Jorge E. E. Cortes
Summary: Gemtuzumab-ozogamicin (GO) is an ADC approved for the treatment of CD33(+) AML. Despite initial recall due to lack of efficacy and hepatotoxicities, subsequent phase 3 studies showed significant survival benefits with lower and fractionated doses of GO in combination with standard chemotherapy. GO at a dose of 6 mg/m(2) was associated with higher grade > 3 hepatotoxicities and VOD compared to 3 mg/m(2). GO has been reapproved in 2017 and is currently being studied for its role in combination therapies and MRD elimination in CD33(+) AML patients.
THERAPEUTIC ADVANCES IN HEMATOLOGY
(2023)
Meeting Abstract
Hematology
Gemma Shay, Michael W. Deininger, Tim H. Bruemmendorf, Jeffrey H. Lipton, Leif Stenke, Eric Leip, Simon Purcell, Andrea Viqueira, Jorge E. Cortes
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Meeting Abstract
Oncology
Richard F. Schlenk, Pau Montesinos, Antonio Romero-Aguilar, Radovan Vrhovac, Elzbieta Patkowska, Hee-Je Kim, Pavel Zak, Po-Nan Wang, James Hanyok, Li Liu, Yasser Mostafa Kamel, Arnaud Lesegretain, Jorge Cortes, Mikkael A. Sekeres, Herve Dombret, Sergio Amadori, Jianxiang Wang, Alexander E. Perl, Mark J. Levis, Harry P. Erba
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Meeting Abstract
Oncology
Ehab Atallah, Michael Mauro, Koji Sasaki, Moshe Levy, Paul Koller, Daisy Yang, Dramane Laine, John Sabo, Ennan Gu, Jorge Cortes
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Meeting Abstract
Oncology
Aram Bidikian, Sreyashi Basu, Zhong He, Himachandana Atluri, Jabra Zarka, Michael Andreeff, Koji Sasaki, Elias Jabbour, Jorge E. Cortes, Padmanee Sharma, Ghayas C. Issa
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Meeting Abstract
Oncology
Joannie Clements, Cristina Ruiz, Andrea Damon, Peter Schuld, Pauline Frank, Cristina Constantinescu, Jorge Cortes
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Meeting Abstract
Oncology
Jorge Cortes, Michael Deininger, Elza Lomaia, Beatriz Moiraghi, Maria Undurraga Sutton, Carolina Pavlovsky, Charles Chuah, Tomasz Sacha, Jeffrey H. Lipton, James McCloskey, Philippe Rousselot, Gianantonio Rosti, Hugues de Lavallade, Christine Rojas, Anna Turkina, Moshe Talpaz, Michael Mauro, Vickie Lu, Alexander Vorog, Jane Apperley
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)